Johns Hopkins University School of Medicine

Decoding the Language of mRNA Stability

We study how the genetic code governs messenger RNA fate—discovering that codon composition is a master determinant of transcript half-lives, with profound implications for gene regulation and therapeutics.

30+Years of Discovery
100+Publications
4Organizations Founded

Co-translational mRNA Decay
& Codon Optimality

Messenger RNA degradation plays a critical role in regulating transcript levels and is a major control point for modulating gene expression. A series of discoveries from our group have uncovered that a significant determinant for RNA degradation is the genetic code itself — a concept we call Codon Optimality.

We showed that mRNA decay rates are dictated by the percentage of codons deemed "optimal," based on the abundance of their cognate tRNAs relative to demand. Optimal codons are decoded rapidly by ribosomes, while non-optimal codons are read more slowly due to limiting tRNA concentration. The rate at which the ribosome decodes an mRNA ultimately determines transcript fate.

Most excitingly, the exact same mRNA sequence can differentially impact stability in distinct cell types — codon optimality is plastic and regulated from cell to cell. We leverage both yeast and mammalian systems to define the molecular interplay between the ribosome and the degradation complex.

Ribosome–Decay Machinery Crosstalk

Defining how the mRNA degradation machinery interacts with the ribosome, and how ribosome conformation signals transcript fate to the Ccr4-Not complex.

mRNA Therapeutics

Translating fundamental discoveries into next-generation mRNA therapies — including poly(A)-tail mimetics and suppressor tRNAs for rare diseases like DMD and haploinsufficiency disorders.

tRNA Biology & mRNA Levels

Exploring how tissue-specific tRNA expression reprograms codon optimality, connecting tRNA metabolism to mRNA stability and neurodevelopmental disorders.

RNA Modifications & Codon Optimality

Investigating how chemical modifications to mRNA — including cytidine acetylation — alter codon optimality and tune translation efficiency across biological contexts.

CellCodon Optimality
ScienceCcr4-Not & Ribosome
NatureCo-translational mRNA Decay
Nat RevCodon Usage Review

Advocacy for mRNA Science

War on the Rocks

Defending Against the Next Bioweapon: The mRNA Imperative

mRNA platforms offer a decisive defensive advantage against engineered biological threats. Congress should restore research funding and the Pentagon should establish mRNA biodefense manufacturing as a strategic priority.

January 2026

Read the essay
Fortune

America Is Handing Its mRNA Lead to China

Investment in U.S. mRNA vaccines collapsed 66% in a single year while other nations build the workforce, infrastructure, and regulatory frameworks to capture growth. Secretary Kennedy's ideological agenda is forfeiting the prize.

March 2026

Read the op-ed
The Wall Street Journal

mRNA Technology Has Cancer in Its Sights

Cancer patients who received mRNA COVID-19 vaccines during treatment lived significantly longer — a finding that could open the door to more-effective cancer therapies with sustained federal investment.

November 2025

Read in WSJ
The Wall Street Journal

RFK Jr.'s Dangerous Attack on mRNA Research

Federal funding for biomedical research pays off by enabling basic discoveries that lead to lifesaving treatments. Pulling back now risks squandering the most promising advances in a generation.

2025

Read in WSJ

Building the mRNA Ecosystem

Alliance for mRNA Medicines

Co-founded the leading global advocacy coalition advancing mRNA technology through policy engagement, public education, and scientific communication. AMM unites industry, academia, and patient advocates across 30+ member organizations.

mrnamedicines.org

Foundation for mRNA Medicines

Co-founded the philanthropic arm dedicated to public education, combatting misinformation, and training the next generation of mRNA scientists and manufacturing professionals.

mrnafoundation.org

Rare REPAIRx Consortium

Founded and leading the Johns Hopkins–Mayo Clinic partnership developing mRNA-CRISPR therapeutics for rare diseases. Industry partners include Danaher, Aldevron, Acuitas Therapeutics, IDT, and Charles River Laboratories.

A Framework for Hope

Tevard Biosciences

Co-founded the biotechnology company pioneering suppressor tRNA-based gene therapies for rare genetic diseases including Duchenne muscular dystrophy, cardiomyopathy, and developmental epileptic encephalopathies.

tevard.com

Legislative Engagement

Producing expert testimony, scientific rebuttals, and briefing materials opposing anti-mRNA legislation across multiple states, including Idaho, Tennessee, Louisiana, South Dakota, and South Carolina. Working with legislative strategy teams to protect mRNA innovation at the state and federal level.

People

Jeff Coller, PhD

Jeff Coller, PhD

Bloomberg Distinguished Professor of RNA Biology & Therapeutics
Director, RNA Innovation Center
Johns Hopkins University School of Medicine & Whiting School of Engineering

A pioneering researcher in RNA biology, Dr. Coller has made fundamental contributions to our understanding of gene expression and mRNA stability. His groundbreaking work demonstrated that the genetic code is a major determinant of mRNA fate in eukaryotes, shifting paradigms in the field and opening new avenues for therapeutic development. He is co-founder of Tevard Biosciences and the Alliance for mRNA Medicines, and leads the REPAIRx consortium — a Johns Hopkins–Mayo Clinic partnership focused on mRNA-CRISPR therapeutics for rare diseases. An elected AAAS Fellow, he received his PhD in Cell and Molecular Biology from the University of Wisconsin-Madison and completed postdoctoral training at the Howard Hughes Medical Institute, University of Arizona.

SM

Sophie Martin, PhD

Research Associate / Senior Scientist

LC

Lana Christensen

BCMB PhD Student

RK

Ryan Kawalerski

MD/PhD Student

SC

Suhee Chang, PhD

Postdoctoral Fellow

ER

Emel Rothzerg, PhD

Postdoctoral Fellow

CL

Christian Lopez

Graduate Student

CK

Chris Kim

Graduate Student

DM

Dylan Miller

Graduate Student

AB

Alisa Bryantseva

Undergraduate

Center Staff

MK

Michelle Kim

Managing Director

SM

Saghana Muraleetharan

Laboratory Manager

LR

Lucas Ralls

Research Technologist

Former Lab Members

Najwa Alhusaini · Iris Ambuehi · Shannon Bailey · Emma Bowie · Dr. Ying-Hsin Chen · Dr. Megan Forrest · Dr. Sarah Geisler · William Hannon · Gavin Hanson · Dr. Wenqian Hu · Carrie Kovalak · Dr. Jay Leipheimer · Lisa Lojek · Dr. Zach Mandell · Ashanti Matlock · Nasreen Naqvi · Dr. Christine Petzold · Dr. Otis Pinkard · Dr. Vlad Presnyak · Michael Prieto · Austin Sponaugle · Dr. Thomas Sweet · Dr. Trinh Tat · Dr. Bahareh Torkzaban

Publications

2026
2025
Trends Mol Med
Gene therapies for neurogenetic disorders
2024
2023
2022
2020
2019
2018
2017
2016
2015
2014
2013
Enzymes
Eukaryotic RNases and their partners in RNA degradation and biogenesis
Springer
The Molecular Biology of Non-coding RNA
2012
2011
2010
2009
2008
2007
2006
2005
2004
2002
2001
2000
1998
View All on PubMed →

Protocols

Our lab protocol book is freely available for download. It includes detailed procedures for RNA extraction, Northern blotting, mRNA stability assays, tRNA-seq, tethered function assays, and other methods developed in our lab over the past two decades.

Download Protocol Book ↓

Contact

Visit the Lab

AddressDepartment of Molecular Biology and Genetics
Johns Hopkins University
725 N. Wolfe St., PCTB 503
Baltimore, MD 21205-2105

Emailjmcoller [at] jhmi.edu

AffiliationsDepartment of Molecular Biology & Genetics
Department of Biomedical Engineering
Institute for NanoBioTechnology
RNA Innovation Center

Invest in RNA Science

Your support fuels fundamental discoveries in RNA biology and accelerates the translation of basic science into life-changing therapies for rare diseases. Gifts of any size directly support graduate students, postdoctoral fellows, and the research infrastructure that makes breakthrough science possible.

Give Now →
Johns Hopkins University

Donations support the Coller Lab and the RNA Innovation Center through the Johns Hopkins giving platform.

Donate Online